DermTech: Kirk Malloy, Mark Capone
DermTech has appointed Kirk Malloy and Mark Capone to its board of directors, effective July 18.
Malloy is currently founder and principal at BioAdvisors, where he provides strategic consulting services to life science, diagnostics and genomics companies. He has spent over 25 years in key leadership positions with Illumina, Biosite, and Qiagen, and most recently served as CEO of Verogen from August 2017 to August 2018 after founding the company. He currently serves as a director for NanoString Technologies and chairman of the board for cancer diagnostics company Tagomics, and is a director for several private genomics tools companies. Malloy earned his BS from the University of Miami, and his MS and PhD from the University of Delaware.
Capone most recently serving as president and CEO of Myriad Genetics. Prior to Myriad, he spent 17 years at Eli Lilly in various leadership positions. Capone currently serves as CEO of Precision Medicine Advisors and is a non-executive board member of Abcam and Owlstone Medical. He holds a BS from Penn State University and an MS in from Massachusetts Institute of Technology.